Osteocyte viability with glucocorticoid treatment: relation to histomorphometry

P N Sambrook, D R Hughes, A E Nelson, B G Robinson, R S Mason

See end of article for authors’ affiliations

Correspondence to: Professor P N Sambrook, Sydney University, Royal North Shore Hospital St Leonards Sydney, Australia 2065; sambrook@med.usyd.edu.au

Accepted 12 May 2003

Glucocorticoid induced osteoporosis is common owing to the effects of glucocorticoids on bone metabolism through multiple pathways, influencing both bone formation and resorption. For the most part, the decreased bone formation is due to direct effects on cells of the osteoblastic lineage, although indirect effects related to sex steroid production are also important. It has been suggested that enhanced osteocyte apoptosis is as an important mechanism of glucocorticoid osteoporosis. In animal models, glucocorticoids have been shown to reduce the formation rate of osteoblasts and osteoclasts and cause the earlier death of osteoblasts. The promotion of apoptosis in osteocytes and in osteoblasts by glucocorticoids is a possible mechanism for the associated rapid increase in fracture susceptibility. As well as undergoing cell death by apoptosis, osteocytes may undergo necrosis when bone age exceeds the upper limit of the lifespan of osteocytes, although the effect of glucocorticoids on osteocyte lifespan independent of apoptosis is unknown.

The direct inhibitory effects of glucocorticoids on bone formation have also been documented in histomorphometric studies, although no studies have correlated osteocyte viability with histomorphometric changes. Osteocytes have two possible fates, remaining in bone until replacement by remodelling or dying through apoptosis, leaving an empty lacuna. Most studies of apoptosis have used transferase mediated biotin dUTP nick end labelling (called the TUNEL reaction) to assess cell death during the limited period of time during which this process is taking place. Assessment of replacement by remodelling can be made by determining osteocyte density. Assessment of the viability of osteocytes is normally monitored by their lactate dehydrogenase (LDH) activity and reduced viability is likely to reflect incipient apoptosis. In this study we assessed osteocyte viability and histomorphometric indices in patients with rheumatoid arthritis treated with glucocorticoids.

SUBJECTS AND METHODS

Patients with rheumatoid arthritis

Iliac crest biopsy specimens were obtained from nine women, aged 61–79 years, who were receiving prednisone treatment (mean daily dose 6.8 mg, range 4–12.5) for rheumatoid arthritis. Before the biopsy, patients received demeclocycline 300 mg three times daily or tetracycline 500 mg three times daily (for 2 days on, 12 days off, 2 days on). Biopsy specimens were taken five days after the last dose. Separate biopsy specimens for histomorphometry and osteocyte viability assessment were obtained from each patient. These specimens were put into 70% ethanol for histomorphometry or normal saline for osteocyte viability processing, respectively.

Controls

Lateral medial plateaus (one female, four male), femoral condyles (one male), or femoral heads (one male) biopsy specimens were obtained from patients, aged 55–79 years, who had had knee or hip replacements for osteoarthritis. These patients did not take tetracyclines before the operation. The biopsy specimens were fixed in 70% ethanol and processed as histomorphometry controls.

Femoral heads were obtained from eight women aged 72–95 years. They were accepted for the study only if the operations were carried out on the day after admission to hospital for subcapital fracture of the femoral neck after minimal trauma or earlier. After removal, the femoral heads were immersed in normal saline. They were kept at 0–4°C until processing that was started within 24 hours of the operation. The femoral head bone was processed for osteocyte viability controls.

Ethical approval for the study was given by the relevant human research ethics committee and informed consent was obtained before biopsy.

Bone histomorphometry

After dehydration in graded ethanol, biopsy specimens were embedded in methyl methacrylate. Serial sections were cut at two levels. They were stained by a modified Masson trichrome method for measurement of the following variables: bone volume/total volume (BV/TV, %), trabecular thickness (Tb Th, μm), trabecular number (Tb No/mm), trabecular spacing (Tb Sp, μm), eroded surface/bone surface (ES/BS, %), osteoid thickness (O Th, μm), osteoblast surface/bone surface (Ob S/BS, %). An acid phosphatase method (naphthol AS-BI phosphate-hexazonium pararosanilin method), with 28 mg / 10 ml of sodium tartrate added to the incubation solution, was used to measure the surface under the osteoclasts (Oc S/BS, %). Sections from biopsy specimens of patients with...
rheumatoid arthritis were left unstained for evaluation of tetracycline labelled surface (LS/BS) under ultraviolet light. All variables were measured with the semiautomatic OsteoMeasure Histomorphometry video system (Osteometrics, Atlanta, USA), which uses the ASMBR Committee nomenclature.15

**Osteocyte viability assessment**

Three to four 300 μm thick sections of biopsy specimens from patients with rheumatoid arthritis were sawn with a Leica 1600 saw microtome (Leica, Sydney) within 1.5 hours of biopsy. Four 300 μm thick sections of femoral head bone were sawn perpendicular to the ligamentum teres about 12 mm from its insertion point (the fovea) with a Microslice 2 precision saw (Metals Research, Cambridge, England). All sections were decalcified in 10% EDTA in Tris buffer 0.05 M, pH 7.0, 6°C for 16 hours. After rinsing thoroughly in Tris buffer, histochemical staining was undertaken using a modification of the method of Wong et al.16 Briefly, 300 μm sections were allowed to react in 0.1% magnesium chloride in Tris buffer 0.05 M, pH 7.0, 50 mmol/l lithium lactate (Sigma), 0.18 mg/l nitroblue tetrazolium (Sigma), and 0.7 mg/l nicotinamide adenine dinucleotide (Sigma) for four hours at 37°C. All sections were fixed in 70% ethanol. Sawn surfaces of bone trabeculae in sections with marrow removed were cleaned with 0.1% HCl for 2×2 minutes to avoid surface artefact. After rinsing in water, sections were stained with methyl green for 15 minutes. After thorough rinsing with water, sections were rolled flat after covering with pieces of polyethylene plastic, clamped between glass slides, oven dried at 60°C for at least three hours, and mounted in Eukitt.

Viable osteocytes were identified by the presence of dark blue formazan granules in the cytoplasm. Non-viable osteocytes were identified by methyl green stained nuclei and the absence of blue granules in the cytoplasm. Empty lacunae were identified by their lacunar walls with phase contrast that was produced by flipping out the condenser lens of the microscope. Osteocytes and lacunae were located by focusing through several planes within 300 μm thick, translucent sections and counted using the OsteoMeasure histomorphometry video system (Osteometrics, Atlanta, USA) at an objective magnification of 20. Statistical analysis was performed using a one tailed Student’s t test. Although osteocytes reside in lacunae within the mineralised matrix of bone, they are not considered inactive cells, but are the mechanosensors in bone.17 Glucocorticoid treated patients were selected from one section for each patient. Similarly, the percentage of non-viable and empty lacunae was significantly increased in glucocorticoid treated patients. In glucocorticoid treated patients, there was a significant correlation between the number of viable cells and OS/BS (r = 0.74, p<0.05).

**DISCUSSION**

Although osteocytes reside in lacunae within the mineralised matrix of bone, they are not considered inactive cells, but rather they probably have a role in transduction of signals of mechanical loading, thereby acting as the mechanosensors in bone.18 Osteocytes are long lived cells, but some of them die as shown by the presence of empty lacunae or lack of enzyme (LDH) activity.19 Decreased osteocyte viability and increased apoptosis will be reflected in decreased osteocyte density, which has been related to age and bone formation rate in healthy (non-glucocorticoid treated) postmenopausal women.20 Although enhanced osteocyte apoptosis has been implicated as an important mechanism of osteoporosis due to oestrogen deficiency,18 and in animal models of glucocorticoid induced osteoporosis,19 there is limited evidence for this in humans.21 These authors identified apoptotic osteoblasts and osteocytes in transiliac biopsy specimens from two patients with glucocorticoid induced osteoporosis, in contrast with biopsy specimens from normal controls, in which no apoptotic cells were detected,20 and apoptotic osteocytes in the femoral heads of patients with glucocorticoid induced osteocytes in glucocorticoid treated patients was based on a total of 705 osteocytes and for hip fracture patients on a total of 795 osteocytes and empty lacunae in eight randomly selected fields from one section for each patient. Similarly, the percentage of non-viable and empty lacunae was significantly increased in glucocorticoid treated patients. In glucocorticoid treated patients, there was a significant correlation between the number of viable cells and OS/BS (r = 0.74, p<0.05).

**RESULTS**

Table 1 shows the histomorphometric indices and table 2 the osteocyte viability. Compared with osteoarthritic controls and normative data for this age group from transiliac bone biopsy specimens,17 glucocorticoid treated subjects had reduced trabecular thickness (p<0.01) and an increase of eroded surfaces (p<0.05) (table 1). The number of viable cells was significantly decreased in glucocorticoid treated patients compared with controls (p<0.05) (table 2). The percentage of viable (LDH positive) osteocytes in glucocorticoid treated patients was based on a total of 705 osteocytes and for hip fracture patients on a total of 795 osteocytes and empty lacunae in eight randomly selected fields from one section for each patient. Similarly, the percentage of non-viable and empty lacunae was significantly increased in glucocorticoid treated patients. In glucocorticoid treated patients, there was a significant correlation between the number of viable cells and OS/BS (r = 0.74, p<0.05).

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Histomorphometric indices (mean (SD))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients receiving GCs (n = 9)</td>
<td>Controls (hip and knee, n = 7)</td>
</tr>
<tr>
<td>BV/TV (%)</td>
<td>19.3 (4.4)</td>
</tr>
<tr>
<td>Tb Th (μm)</td>
<td>82.8 (12.8)**</td>
</tr>
<tr>
<td>Tb N0/mm</td>
<td>2.30 (0.30)</td>
</tr>
<tr>
<td>Tb Sp (μm)</td>
<td>357.2 (72.2)</td>
</tr>
<tr>
<td>ES/BS (%)</td>
<td>7.1 (4.4)*</td>
</tr>
<tr>
<td>Oc S/BS (%)</td>
<td>1.25 (1.37)</td>
</tr>
<tr>
<td>OS/BS (%)</td>
<td>5.8 (3.4)</td>
</tr>
<tr>
<td>O Th (μm)</td>
<td>5.4 (1.6)</td>
</tr>
<tr>
<td>Ob S/BS (%)</td>
<td>0.97 (1.0)</td>
</tr>
<tr>
<td>LS/BS</td>
<td>4.3 (3.9)</td>
</tr>
</tbody>
</table>

Significantly different from both sets of controls: *p<0.05; **p<0.01.

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Osteocyte viability (mean (SD))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients receiving GCs (n = 9)</td>
<td>Hip fracture controls (n = 8)</td>
</tr>
<tr>
<td>Viable</td>
<td>620 (93)*</td>
</tr>
<tr>
<td>Non-viable</td>
<td>34 (43)</td>
</tr>
<tr>
<td>Empty lacunae</td>
<td>52 (49)</td>
</tr>
<tr>
<td>Cells (n)</td>
<td>706 (107)</td>
</tr>
<tr>
<td>Viable (%)</td>
<td>88 (8%)</td>
</tr>
<tr>
<td>Non-viable (%)</td>
<td>5 (6)</td>
</tr>
<tr>
<td>Empty lacunae (%)</td>
<td>7 (5)</td>
</tr>
<tr>
<td>Non-viable-empty lacunae (%)</td>
<td>1268 (64)</td>
</tr>
</tbody>
</table>

Significantly different from control group: *p<0.05.
osteonecrosis. We found the number of viable osteocytes was significantly decreased in glucocorticoid treated patients compared with controls, consistent with this hypothesis.

In the study presented here the numbers of patients investigated are greater, but the controls are not ideal. For practical reasons, relating to the difficulty of ethically justifying an iliac crest biopsy in normal subjects, the control biopsy specimens were from the femoral heads rather than the iliac crest. Although there have been reported differences in osteocyte viability in the spine compared with the hip, the controls for osteocyte viability were all female, but somewhat older than the glucocorticoid treated group, which would be likely to decrease the chance of finding viable osteocytes in that group as viability has been reported to decrease with age. These control patients had also sustained a hip fracture, which would also not be expected to enhance osteocyte viability in the removed femoral heads. Moreover, our control data are consistent with the percentage total occupied lacunae at age 80 reported by Qui et al. of about 90%. Moreover, Qui et al. recognised that some stained osteocytes might have recently died by apoptosis. In our study we quantified the percentage of dead but stainable osteocytes by methyl green nuclei staining and lack of LDH product. Of the 12% non-viable cells and empty lacunae group in glucocorticoid treated patients, 5% were recently dead. In contrast, in the controls 2% of the 6% were recently dead. These findings suggest that glucocorticoid treated patients have an increased number of non-viable (recently dead) osteocytes.

The controls used for histomorphometry were better age matched but were predominantly male. For this reason, data from age matched female controls from the study of Recker et al. using the Osteomeasure system, were also considered. The trabecular thickness and eroded surface were similar to those of the current controls and different from the glucocorticoid treated group.

Reduced bone formation is characteristic of glucocorticoid induced osteoporosis. The effect of glucocorticoids on osteoclastic activity is rather more variable. Osteoclastic activity is mostly increased in this condition, though not in all studies. Glucocorticoids have been reported to reduce osteoclastogenesis in vitro, though possibly only at very high doses, and more consistently to increase osteoclast lifespan. The increased osteoclastic activity in the patients reported here might be explained by an increase in osteoclast lifespan in the presence of glucocorticoids.

The clinical significance of the observed decrease in osteocyte viability in patients treated with glucocorticoids is unclear at this time. Nevertheless, it is reasonable to speculate that decreased osteocyte viability might diminish bone ability to sense mechanical load and so lead to reduced bone mass. The observed correlation between osteocyte viability and osteoid surface may support this proposal. Decreased osteocyte viability might also decrease the ability to sense or repair microdamage and so contribute to an increased propensity to fracture for a given bone mineral density. Loss of osteocyte viability in large areas might also lead to so-called avascular osteonecrosis.

**ACKNOWLEDGEMENTS**

Erin Martin is acknowledged for technical assistance.

---

**REFERENCES**

Osteocyte viability with glucocorticoid treatment: relation to histomorphometry

P N Sambrook, D R Hughes, A E Nelson, B G Robinson and R S Mason

doi: 10.1136/ard.2003.008839

Updated information and services can be found at: http://ard.bmj.com/content/62/12/1215

These include:

References
This article cites 19 articles, 0 of which you can access for free at: http://ard.bmj.com/content/62/12/1215#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Degenerative joint disease (4641)
- Musculoskeletal syndromes (4951)
- Osteoarthritis (931)
- Pathology (444)
- Calcium and bone (725)
- Clinical diagnostic tests (1282)
- Connective tissue disease (4253)
- Immunology (including allergy) (5144)
- Osteoporosis (137)
- Radiology (1113)
- Rheumatoid arthritis (3258)
- Surgical diagnostic tests (431)

Notes

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/